Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ).
Beijing Biostar Pharmaceuticals Co., Ltd. has announced the resumption of trading of its shares on the Hong Kong Stock Exchange following a suspension due to delayed publication of its 2024 annual results. The company has completed its annual audit and published the results, addressing previous issues with IPO proceeds and implementing measures to prevent future oversights, thus ensuring normal operations and compliance with listing requirements.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is engaged in the research, development, manufacturing, and sale of innovative drugs. The company operates within the pharmaceutical industry, focusing on creating advanced medical solutions.
Average Trading Volume: 371,000
Technical Sentiment Signal: Strong Sell
For a thorough assessment of 2563 stock, go to TipRanks’ Stock Analysis page.